Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Medical Device

Roche’s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients

Fineline Cube May 15, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA®...

Company Deals

Novo Nordisk and Septerna Ink $2.2 Billion Deal for GPCR Drug Discovery

Fineline Cube May 15, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) and Septerna, Inc. (NASDAQ: SEPN) announced an exclusive...

Company

Sanofi Announces $20 Billion Investment in US R&D and Manufacturing by 2030

Fineline Cube May 15, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its intention to invest at least $20...

Company Deals

GSK Signs Deal to Acquire Boston Pharmaceuticals’ Efimosfermin Alpha

Fineline Cube May 14, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP...

Company Deals

Acchrom Technologies Secures Pre-Series B Funding to Expand Chromatography Solutions

Fineline Cube May 14, 2025

Beijing-based Acchrom Technologies Co., Ltd., a specialist in chromatography, has reportedly secured over RMB 100...

Company Deals

Ningbo Jansen Files STAR IPO for MRI Technology Expansion

Fineline Cube May 14, 2025

China-based Ningbo Jansen NMR Technology Co., Ltd. announced that its initial public offering (IPO) filing...

Company Drug Medical Device

China’s Q1 2025 Pharmaceutical Exports Rise 4.39% Despite Import Decline

Fineline Cube May 14, 2025

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Deals

Porton Pharma Collaborates with Henan Hualong for MATC Therapy Development

Fineline Cube May 14, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has entered into a...

Company

Bayer Reports Flat Q1 Revenue amid Crop Science Decline

Fineline Cube May 14, 2025

German pharmaceutical and chemical giant Bayer (ETR: BAYN) released its Q1 2025 financial report, recording...

Company Drug

Medilink Therapeutics Gains FDA IND Approval for VEGF-Targeted ADC YL242

Fineline Cube May 14, 2025

Suzhou-based Medilink Therapeutics announced that it has received Investigational New Drug (IND) approval from the...

Company Drug

Zhongsheng Pharma’s Anruiwei Shows Promising Results in Pediatric Influenza A Study

Fineline Cube May 14, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the topline analysis data from the...

Company Drug

Sinovac Biotech Gains Hong Kong Approval for Influenza Vaccines

Fineline Cube May 14, 2025

China-based Sinovac Biotech Ltd (NASDAQ: SVA) announced that it has received marketing approvals from the...

Company

InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable

Fineline Cube May 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording...

Drug Policy / Regulatory

NMPA Releases 92nd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube May 14, 2025

The National Medical Products Administration (NMPA) has released the 92nd batch of reference drugs for...

Company Deals

Gan & Lee Pharmaceuticals Signs PDP Agreement with Brazilian Health Ministry

Fineline Cube May 14, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) announced the signing of Parcerias para o Desenvolvimento Produtivo...

Company Drug

Zelgen Biopharmaceuticals Submits New Indication Application for Jacktinib in Severe Alopecia Areata

Fineline Cube May 14, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has submitted a new...

Company Deals

Meheco Acquires Golden Harvest for E-commerce Expansion

Fineline Cube May 14, 2025

China Meheco Group Co., Ltd (SHA: 600056) announced the acquisition of 100% stake in Beijing...

Company

JD Healthcare Reports 25.5% Revenue Growth in Q1 2025

Fineline Cube May 14, 2025

JD Healthcare (HKG: 6618), a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), released its...

Company Drug

Ocumension Therapeutics Receives Approval for OT-703 Real-World Study in China

Fineline Cube May 14, 2025

Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) announced that it has received approval in China...

Company

Legend Biotech’s Q1 2025 Results Highlight Carvykti Sales Growth

Fineline Cube May 14, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue...

Posts pagination

1 … 108 109 110 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.